Fractyl Health, Inc. Common Stock (GUTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has a cash flow conversion efficiency ratio of 7.147x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.71 Million) by net assets ($-3.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fractyl Health, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Fractyl Health, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Fractyl Health, Inc. Common Stock (GUTS) total liabilities for a breakdown of total debt and financial obligations.
Fractyl Health, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RoboRobo Co. Ltd
KQ:215100
|
0.006x |
|
N. Varveris-Moda Bagno S.A
AT:MODA
|
0.043x |
|
Moda-InnoChips Co. Ltd
KQ:080420
|
-0.011x |
|
Aeternal Mentis SA
MC:AMEN
|
-0.051x |
|
Korea Cast Pip
KO:000970
|
0.004x |
|
Torrid Holdings Inc
NYSE:CURV
|
0.023x |
|
Lyko Group A
ST:LYKO-A
|
0.325x |
|
Deutsch Motors Inc
KQ:067990
|
0.043x |
Annual Cash Flow Conversion Efficiency for Fractyl Health, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Fractyl Health, Inc. Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Fractyl Health, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $28.42 Million | $-65.52 Million | -2.305x | -1849.78% |
| 2023-09-30 | $-325.06 Million | $-42.82 Million | 0.132x | -28.12% |
| 2022-09-30 | $-252.32 Million | $-46.24 Million | 0.183x | +14.65% |
| 2021-09-30 | $-209.32 Million | $-33.46 Million | 0.160x | +107.69% |
| 2020-09-30 | $14.95 Million | $-31.07 Million | -2.078x | -1179.23% |
| 2019-09-30 | $-144.00 Million | $-27.73 Million | 0.193x | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel ade… Read more